ECG changes in adults using methamphetamine with and without psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective cohort study conducted on the closed inpatient psychiatric ward at Elazığ Mental Health and Diseases Hospital enrolling adults with DSM-5-TR diagnoses of Methamphetamine Use Disorder or Methamphetamine-Induced Psychotic Disorder and positive urine methamphetamine. Standard 12-lead ECGs will be recorded at hospital admission and again during remission prior to discharge, and parameters such as QTc, QT dispersion, Tp-e interval, Tp-e/QTc ratio, ST changes, and P-wave dispersion will be measured. Groups will be compared to determine whether methamphetamine-induced psychosis is associated with greater ECG abnormalities and inferred cardiac risk compared with methamphetamine use without psychosis. Subjects with major medical comorbidities (e.g., hypertension, diabetes, known cardiac disease) or primary psychiatric disorders other than the specified diagnoses are excluded to reduce confounding.

Why it matters

Who can join: the full rules

1. For Methamphetamine Use Disorder (MUD) Group:

   \*Inclusion Criteria:
   * Diagnosis of MUD according to DSM-5-TR
   * Medication-free for at least one month prior to admission
   * Age ≥ 18 years and \<65 years
   * Provided informed consent

   For Methamphetamine Use Disorder (MUD) Group:

   \*Exclusion Criteria:

   • Hypertension
   * Diabetes mellitus
   * Chronic kidney disease
   * Rheumatoid arthritis
   * Systemic lupus erythematosus
   * Cardiac illness
   * Severe neurological disorders
   * Immunological or systemic illness
   * Primary psychiatric disorders other than MUD
   * Alcohol use disorder
2. For Methamphetamine-Induced Psychotic Disorder (MP) Group:

   \*Inclusion Criteria:
   * Diagnosis of MP according to DSM-5-TR
   * Medication-free for at least one month prior to admission
   * Age ≥ 18 years and \<65 years
   * Provided informed consent

   For Methamphetamine-Induced Psychotic Disorder (MP) Group:

   \*Exclusion Criteria:
   * Hypertension
   * Diabetes mellitus
   * Chronic kidney disease
   * Rheumatoid arthritis
   * Systemic lupus erythematosus
   * Cardiac illness
   * Severe neurological disorders
   * Immunological or systemic illness
   * Primary psychiatric disorders other than MP
   * Alcohol use disorder
3. For Healthy Control Group:

   \*Inclusion Criteria:
   * No psychiatric diagnosis
   * No systemic or immunological illness
   * Medication-free for at least one month
   * Age ≥ 18 years and \<65 years
   * Provided informed consent

   For Healthy Control Group:

   \*Exclusion Criteria:

   • Hypertension
   * Diabetes mellitus
   * Chronic kidney disease
   * Rheumatoid arthritis
   * Systemic lupus erythematosus
   * Cardiac illness
   * Severe neurological disorders
   * Immunological or systemic illness
   * Primary psychiatric disorders other than schizophrenia
   * Alcohol/drug/substance use

Where it's running

• Elazığ Mental Health and Diseases Hospital
  Elâzığ, Elâzığ, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist
• Email: mhorum@hotmail.com
• Phone: +905382207558

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tirzepatide for methamphetamine use disorder (phase 2)

  This phase 2 trial tests whether weekly tirzepatide injections can help adults with moderate to severe methamphetamine use disorder reduce use and improve outcomes compared with placebo.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Los Angeles, California and 3 other locations · NCT07825857

• Psilocybin Therapy for MeUD and HIV

  This study tests whether a single psilocybin dose, paired with motivational support therapy, can help people with HIV and moderate-to-severe methamphetamine use disorder stop using methamphetamine.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07756736

• Psychiatric Symptoms in Methamphetamine Psychosis With or Without Lifetime Cannabis Use

  This study tests whether lifetime cannabis use changes the course and severity of psychiatric symptoms in people hospitalized with methamphetamine-induced psychosis.

  Recruiting Elazığ Mental Health and Diseases Hospital · Elâzığ, Elâzığ and 1 other locations · NCT07459270

• What predicts psychiatric symptoms over one year in methamphetamine-induced psychosis

  This will see if social, family, and individual factors predict changes in psychiatric symptoms over one year in adults with methamphetamine-induced psychosis.

  Recruiting Elazığ Mental Health and Diseases Hospital · Elâzığ, Elâzığ · NCT07459257

• Benefits of reducing methamphetamine use

  This study will try contingency management to see if cutting back on methamphetamine improves physical, mental, and social health for adults with moderate-to-severe methamphetamine use disorder.

  Recruiting University of Kentucky · Lexington, Kentucky · NCT07226596

• CHAMPION: Combining HIV Prevention and Meth Treatment for HIV-Negative MSM

  This pilot test will see if two mobile health tools can help HIV-negative men who have sex with men who use meth take PrEP more consistently.

  Recruiting University of California, San Diego · San Francisco, California · NCT07213258

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.